Peer Review History
| Original SubmissionFebruary 5, 2020 |
|---|
|
PONE-D-20-03358 Decision-making approaches used by UK and international health funding organisations for allocating research funds: A survey of current practice PLOS ONE Dear Dr. Meadmore, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jul 11 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Shelina Visram, PhD, MPH, BA Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Please include your tables as part of your main manuscript and remove the individual files. Please note that supplementary tables should remain as separate "supporting information" files [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: I Don't Know Reviewer #2: N/A ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Abstract – needs to refer more clearly to which types of funders were participants; for example, ‘other international countries’ is a little vague, can you be more explicit? The way in which the funders are referred to in the abstract suggests that they are relatively homogenous in terms of the types of health research that are funded – can you be more clear if the focus was, for example, biomedical health research, research on wider determinants of health? or both and more? I think that the abstract could also more clearly demonstrate the value and need for this research – which is this important to know? One of the conclusions is about a solid evidence base but could have been clearer how this came from the results. Also, I wasn’t clear what “reviewer diversity that were integral to current practice or important for future practice” meant – can you clarify? Need for /value of this research needs to be more clearly demonstrated at the start of the piece. It is mentioned that difficult decisions need to be made – can you be more clear what these are? decisions between different types of health research? prevention vs treatment? biomedical vs wider determinants research? There are fundamental differences in ontology/epistemology within the field of health research that could for example at least be alluded to? Can you be more clear about some of the fundamental difficulties in the health field in particular? There is an assertion that there have been wider developments that have happened, mentioning “public contribution and new data legislations” – can you explain more clearly why these are significant, give some examples? And you indicate that peer review has undergone limited change but then go on to give some examples of change – this seems a little inconsistent. Can you be clearer what the need and value of this research is? Methods – can you be more clear what you mean by wider reach – wider reach that what? (do you just mean a wide reach and where? in the UK, globally? Also, can you explain what you mean by phemenological approach? You refer to the survey questions being developed by a variety of stakeholders but these seem only to be NIHR / NIHR team members, which does not seem that various; I would recommend being more clear about this and how the survey was developed – how was previous research/literature used to develop the survey questions? What is a ‘think aloud pilot’? It would be useful earlier in the methods to indicate who the intended respondents of the survey were. Can you be more clear what you mean by data being screened for quality? What did this involve? Are you suggesting that some data was removed on this basis? How did wider literature on the topic inform the data analysis? Results / discussion – some interesting findings are highlighted and points discussed. At times, there is use of terminology such as “right questions, teams and research proposals are funded” which suggests that there is a ‘right’ answer to what should be funded. It is not immediately clear that it is always the case that there is a ‘right’ answer – as decision-making involves making value-based choices between alternative, particularly in the health field where, for example, decisions might be made between biomedical research and health-related social science research – what would be the ‘right’ decision here? I think that some of the discussion needs to be more nuanced and reflective of this type of issue. Earlier on the piece there is mention of a “broad range of health areas, including ageing, neurodegenerative diseases, cancer, diabetes, meningitis, health technology, HIV and AIDS, heart disease and stroke. They covered basic science through to applied clinical research as well as health service delivery, and included disease-specific programmes, public health and global health.” This breadth and complexity of the health field needs to be recognised more in the discussion I think; with some recognition that this relates also to your points about ‘expertise’ - if health funding covers all the above, it is of course challenging to cover all these areas? What other aspects of ‘expertise’ are also important? What about contextual knowledge – which can be particularly important, for example, in evaluative research/implementation research where context can shape how interventions are received/adopted/rolled out/scaled up? Recognition of some of these issues would show more reflection/consideration of how the data in the study is important? Reviewer #2: Thank you for the opportunity to review this manuscript, which is well-written and has the potential to contribute to the literature on decision-making by research funders. I have a number of suggested revisions that I believe will improve the manuscript: ABSTRACT: I find the use of the terms ‘current decision-making processes’ and ‘alternatives’ confusing here. If some are using these alternatives then surely they are also part of the current processes? The authors seem to be making some assumptions about the ‘normal’ way of doing things and more ‘unusual’ approaches. If peer review is seen as the ‘norm’ and other approaches are somehow more ‘innovative’ then this needs to be made clear in the abstract. INTRODUCTION: The final sentence of the first paragraph (lines 57-60) needs to be supported by evidence/relevant citations. METHODS: The survey development and piloting process appears to have been rigorous and is well-described. However, I would have liked to see the ‘think aloud’ pilot explained further, ideally with reference to the literature. A minor point but the sentence at lines 144-146 (and the following sentence) could be re-worded to avoid using the words ‘organisations’ and ‘targeted’ multiple times. 76 health research organisations were identified – across how many countries? It is not entirely clear who potential respondents were, e.g. where emails were person-specific, were these targeted towards chairs of funding panels, administrative support staff, etc? Lines 174-175: how exactly were multiple responses from the same organisation ‘merged’? Were any in conflict? The description of the analytical process is confusing, particularly the suggestion that inconsistencies or limited responses were excluded. What exactly does this mean? It would be helpful if the authors could say more about this because it leaves the reader wondering if they excluded responses that did not fit with their a priori assumptions. How does this fit with the phenomenological approach (which is mentioned at lines 113-115) and thematic analysis? Figure 1 – providing a textbook illustration of the thematic analysis process – is not necessary. RESULTS: Related to the point above about excluding certain responses, I am not clear why only 31 of 35 responses were included (resulting in the exclusion of 1 of 24 organisations). Figure 2 is helpful but does not make clear what exclusion on the basis of quality means. It is however very interesting that the non-targeted recruitment resulted in few additional responses; this is an important learning point for other researchers that I think the authors should pick up on in their discussion. Much of the information in the sub-section on respondent characteristics might be better presented in the form of a table. Using n for number of responses is confusing where this actually relates to the number of organisations, e.g. lines 221-223. This also applies when reporting qualitative findings; I am really not clear what n=28 means at line 230. Presumably this denotes the number of usable survey responses that included qualitative data, but this is not made clear in the text. I was surprised not to see quotes attributed by country or any discussion of inter-country differences in the survey findings. Redaction of the quote at lines 372-373 has obscured the meaning. Please add some descriptive text to indicate what [name] relates to, i.e. is it an organisation, a process, etc? DISCUSSION: The discussion is good, with clear recommendations. As stated above, I would like to see some discussion on any inter-country differences and also lessons learned for researchers conducting similar studies. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-20-03358R1 Decision-making approaches used by UK and international health funding organisations for allocating research funds: A survey of current practice PLOS ONE Dear Dr. Meadmore, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== ACADEMIC EDITOR: Thank you for making the revisions to this paper. R1 is happy that all previous comments have been addressed. Unfortunately the original R2 was not available and so a new reviewer was approached to look at the revised manuscript. They have suggested an additional minor change/clarification that should be very quick and easy to address, and should help to make description of the study design more rigorous. ============================== Please submit your revised manuscript by Oct 03 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Shelina Visram, PhD, MPH, BA Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #2: All comments have been addressed Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #2: (No Response) Reviewer #3: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #2: (No Response) Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #2: (No Response) Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #2: (No Response) Reviewer #3: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #2: (No Response) Reviewer #3: Thank you for the opportunity to review this paper. It is well written, methodologically sound and discusses an engaging issue well. The comments to the author have been clearly addressed and result in a more rigorous paper. Apologies for adding additional feedback, but one minor issue could be discussed in order to ensure full rigour. Your paper states that you took a mixed methods approach to data analysis, but then give only detail of the analysis for qualitative and quantitative strands as separate entities. There is no discussion of synthesis of the strands. If this was carried out, can it be detailed (e.g. was the analysis sequential or prioritised in any way)? If it was not, can this absence be justified in relation to your research question and design? Thanks again - and apologies for the minor revisions. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
Decision-making approaches used by UK and international health funding organisations for allocating research funds: A survey of current practice PONE-D-20-03358R2 Dear Dr. Meadmore, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Shelina Visram, PhD, MPH, BA Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
| Formally Accepted |
|
PONE-D-20-03358R2 Decision-making approaches used by UK and international health funding organisations for allocating research funds: A survey of current practice Dear Dr. Meadmore: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Shelina Visram Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .